Paul Hastings, president and CEO of Oncomed Pharmaceuticals, discusses the controversial topic of cancer stem cells, what he calls the root of the tumor. He also talks about how his company is working with other pharmaceutical companies who are helping with Oncomeds biotech work.
Tech Nation w/Moira Gunn
